dc.contributor
Institut Català de la Salut
dc.contributor
Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Malhotra Sareen, Sunny
dc.contributor.author
Martín Miras, Mari Carmen
dc.contributor.author
Pappolla, Agustin
dc.contributor.author
Comabella Lopez, Manuel
dc.contributor.author
Montalban, Xavier
dc.date.issued
2023-08-23T07:24:39Z
dc.date.issued
2023-08-23T07:24:39Z
dc.date.issued
2023-07-22
dc.identifier
Malhotra S, Martín Miras MC, Pappolla A, Montalban X, Comabella M. Liquid Biopsy in Neurological Diseases. Cells. 2023 Jul 12;12(14):1911.
dc.identifier
https://hdl.handle.net/11351/10129
dc.identifier
10.3390/cells12141911
dc.identifier
001035122300001
dc.description.abstract
Liquid biopsy; MicroRNA; Neurological diseases
dc.description.abstract
Biòpsia líquida; MicroARN; Malalties neurològiques
dc.description.abstract
Biopsia líquida; MicroARN; Enfermedades neurológicas
dc.description.abstract
The most recent and non-invasive approach for studying early-stage biomarkers is liquid biopsy. This implies the extraction and analysis of non-solid biological tissues (serum, plasma, saliva, urine, and cerebrospinal fluid) without undergoing invasive procedures to determine disease prognosis. Liquid biopsy can be used for the screening of several components, such as extracellular vesicles, microRNAs, cell-free DNA, cell-free mitochondrial and nuclear DNA, circulating tumour cells, circulating tumour DNA, transfer RNA, and circular DNA or RNA derived from body fluids. Its application includes early disease diagnosis, the surveillance of disease activity, and treatment response monitoring, with growing evidence for validating this methodology in cancer, liver disease, and central nervous system (CNS) disorders. This review will provide an overview of mentioned liquid biopsy components, which could serve as valuable biomarkers for the evaluation of complex neurological conditions, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, stroke, traumatic brain injury, CNS tumours, and neuroinfectious diseases. Furthermore, this review highlights the future directions and potential limitations associated with liquid biopsy.
dc.description.abstract
S.M. was supported by the grant from Instituto Salud Carlos III (PI20/01697).
dc.format
application/pdf
dc.relation
https://doi.org/10.3390/cells12141911
dc.relation
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI20%2F01697
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Marcadors bioquímics
dc.subject
Sistema nerviós central - Malalties - Diagnòstic
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
dc.subject
DISEASES::Nervous System Diseases::Central Nervous System Diseases
dc.subject
Other subheadings::Other subheadings::/diagnosis
dc.subject
CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central
dc.subject
Otros calificadores::Otros calificadores::/diagnóstico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN
dc.title
Liquid Biopsy in Neurological Diseases
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
